LUCIUS 卢修斯 哌柏西利 Palbociclib转移性乳腺癌

哌柏西利

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Palbociclib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compesition:
Each capsule contains Palbociclib.

转移性乳腺癌

odicatlon:

LUCIUS
PHARMACEUTICALS

eatticil oi dduit patlenis with normone receptor
peine, Fuman epidermal grow th factor
receptor 2 HEK2)-bezative adyanced or metastatic
breast cancer in combrnation with
w an aromatase inhibitor as iniial endoerine.hscs

LuciPalbo

tollowine endocrine iha

LaciPalbo capsules are taken orally with food in

Palbociclib Capsules

combination with an aromatese inhibitor or falvestrant.

FDA批准

*Recommended starting dose: 125 me ance daily ta
with food for 21 davs follnsad ka

125mg

*Dosing interruntion and/or dose reductions are
y/days oft treatment

toon indrvidual salely and
1oerapility.

Starage: in a dry place and store at 20°C ho 25°C
Warning:

21 Capsules

Kcep medicine ost of reach of Children. Do not
administer LaciPalbo durina Preonancy and Lactatios.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:
LUCIUS

权威认证

Thongmang village, Xaythany distriel,
Vientiane Capital, Laos
Warning : To he sold by retail on prescription
of registered chssicia

byheaanciaas only, and as directed

Rx Only

口碑质量

适应症:
适用于治疗激素受体(HR)阳性、人类表皮生长因子受体2(HER2)阴
性的晚期或转移性乳腺癌的成年患者,联合用药:
·与芳香化酶抑制剂联合使用,作为绝经后女性或男性的初始内分泌治
疗:

·与氟维司群联合使用,用于内分泌治疗后病情进展的患者。
推荐剂量:
与芳香化酶抑制剂或氟维司群一起口服:
·建议起始剂量:每日一次,每次125mg,随餐服用,连续21天,然后停
药7天。
·根据个人安全性和耐受性,建议中断给药和/或减少剂量。